CIK THERAPY FOR
LIVER CANCER (HCC)
Clinical evidence, patient eligibility, and combination strategies for CIK cell therapy in hepatocellular carcinoma โ where CIK has the most robust evidence base of any adoptive cell therapy for a solid tumour.
analyticsAt a Glance
- check_circleCIK has the strongest RCT evidence base in HCC of any adoptive cell therapy for solid tumours
- check_circleUsed post-resection, post-TACE, and post-RFA to reduce recurrence and improve survival
- check_circleMultiple Chinese RCTs demonstrate significant disease-free and overall survival benefits
- check_circleAvailable at major hepatobiliary oncology centres in China โ coordinated via CancerFax
Why CIK Therapy Is Particularly Relevant in HCC
Hepatocellular carcinoma has a high recurrence rate even after curative-intent treatment. Post-resection 5-year recurrence rates exceed 70% in many series, and post-TACE response durability is limited. CIK therapy addresses this gap โ not by replacing locoregional treatment, but by reinforcing the immune surveillance that prevents residual or micrometastatic disease from establishing recurrence.
โIn HCC, the battle does not end with TACE or resection โ CIK therapy continues the fight at the cellular level.โ
Post-Resection Adjuvant
After surgical resection of HCC, CIK therapy administered as adjuvant immunotherapy has demonstrated significant improvement in disease-free survival and time to recurrence in multiple randomised trials โ targeting residual micro-disease that imaging cannot detect.
Post-TACE Combination
TACE (transarterial chemoembolisation) causes immunogenic tumour cell death that may enhance the anti-tumour activity of subsequently infused CIK cells. Multiple RCTs show that CIK following TACE improves both tumour response and overall survival vs TACE alone.
Post-RFA Adjuvant
Radiofrequency ablation (RFA) creates a zone of tumour necrosis and releases tumour antigens โ a setting that may prime the immune environment for CIK activity. Post-RFA CIK infusion has shown improved recurrence-free survival in Chinese cohort studies.
Unresectable HCC โ Palliative Combination
For patients with intermediate-to-advanced HCC not eligible for resection or ablation, CIK in combination with sorafenib, TACE, or hepatic arterial infusion chemotherapy (HAIC) has shown modest OS benefits in selected trials.
Clinical Efficacy Data: CIK in HCC
Selected key outcomes from randomised controlled trials of CIK therapy in hepatocellular carcinoma. All data from published Chinese academic centre trials.
Post-Resection HCC (Lee et al. Lancet Oncol 2015)
230 patients, post-curative resection HCC. CIK adjuvant vs observation. Source: Lee JH et al, Lancet Oncology 2015.
- Recurrence-free survival improvement (CIK)Significant HR 0.63
- Overall survival improvement (CIK)Significant HR 0.21 (subgroup)
- Observation arm (control)Reference
CIK + TACE vs TACE Alone (Pooled RCT Data)
Pooled analysis of RCTs comparing TACE+CIK vs TACE alone in HCC. Source: Multiple Chinese RCTs, systematic reviews 2014โ2022.
- 1-year OS (TACE + CIK)~78โ82%
- 1-year OS (TACE alone)~60โ68%
How CIK Therapy Fits Into HCC Treatment Pathways
CIK therapy is sequenced around โ not instead of โ the primary locoregional or surgical treatment for HCC. Timing matters for maximum immunological synergy.
- 1
Primary Treatment (Surgery, TACE, or RFA)
The patient undergoes resection, TACE, or RFA as primary treatment. These procedures reduce tumour burden and, in the case of TACE and RFA, trigger immunogenic tumour cell death that may enhance subsequent CIK activity.
- 2
Blood Collection for CIK Manufacturing
Typically 2โ4 weeks post-primary treatment (allowing partial immune recovery), peripheral blood is collected via leukapheresis or venepuncture. CIK manufacturing begins in the GMP laboratory.
- 3
CIK Expansion and QC (14โ21 days)
CIK cells are expanded ex vivo using IFN-ฮณ, anti-CD3 antibody, and IL-2. The completed product undergoes viability, sterility, and identity quality control before release.
- 4
First CIK Infusion Cycle
Infusions are administered intravenously over 30โ60 minutes. A typical cycle involves multiple infusions over 3โ5 consecutive days, followed by a rest period.
- 5
Follow-Up Imaging and Response Assessment
AFP levels, CT/MRI imaging, and liver function tests are monitored 4โ8 weeks after each cycle to assess response and guide further treatment decisions.
- 6
Subsequent CIK Cycles (Maintenance)
Most protocols involve 3โ6 CIK cycles over 6โ18 months as maintenance therapy. The number of cycles is guided by response, tolerance, and the treating oncologist's protocol.
HCC Patient Eligibility for CIK Therapy
CIK therapy is applicable across a broader range of HCC patients than most advanced therapies โ but several factors influence timing and appropriateness.
| Patient Factor | Suitable for CIK? | Notes |
|---|---|---|
| Post-resection, clear margins | โ Yes โ strong evidence | Adjuvant CIK significantly reduces recurrence in RCTs |
| Post-TACE (complete or partial response) | โ Yes โ strong evidence | Most widely studied CIK-HCC combination |
| Post-RFA | โ Yes โ good evidence | Improves recurrence-free survival in cohort studies |
| Unresectable HCC + sorafenib | โ Yes โ combination evidence | CIK + sorafenib shows OS benefit vs sorafenib alone |
| Active hepatitis B/C (uncontrolled) | โ Conditional | Viral load must be controlled before CIK; hepatologist input required |
| Child-Pugh B cirrhosis | โ Conditional | CIK is generally tolerated but requires careful assessment of liver reserve |
| Child-Pugh C / end-stage liver failure | โ Not appropriate | Insufficient immune and hepatic reserve for CIK therapy |
HCC and CIK โ Key Numbers
Contextual figures that frame the clinical importance of post-treatment immune reinforcement in hepatocellular carcinoma.
- >70%5-year recurrence rate after curative HCC resectionThe high post-surgical recurrence rate is the primary driver for adjuvant CIK use in HCC.
- HR 0.63Recurrence-free survival hazard ratio with adjuvant CIK (Lancet Oncol 2015)A 37% reduction in recurrence risk โ the most robust single-trial evidence for CIK in any solid tumour.
- 2ndMost common cause of cancer death globallyHCC accounts for ~800,000 deaths per year โ predominantly in Asia, where CIK evidence has been generated.
More from the CIK Cell Therapy Resource Library
Explore related CIK guides โ from the patient introduction to the manufacturing process and comparisons with other therapies.
Frequently Asked Questions: CIK for Liver Cancer
When after TACE should CIK therapy begin?
Most published protocols initiate CIK cell collection 2โ4 weeks after TACE, once initial inflammatory response has settled and the patient's general condition is stable. Manufacturing takes a further 14โ21 days, meaning first infusion typically occurs 4โ6 weeks post-TACE. Your treating oncologist will determine the optimal timing based on your response to TACE, liver function, and overall clinical status.
Can CIK therapy be combined with immunotherapy checkpoint inhibitors like atezolizumab?
The combination of CIK with PD-1/PD-L1 checkpoint inhibitors (such as atezolizumab or sintilimab) is biologically rational and is being actively explored in Chinese clinical trials. Checkpoint inhibition may enhance CIK efficacy by relieving T-cell exhaustion in the tumour microenvironment. This combination is not yet standard of care but may be available within clinical trial frameworks at specialist centres. CancerFax can identify centres offering this combination.
Does CIK therapy affect liver function in patients with underlying cirrhosis?
CIK therapy has generally been well tolerated in patients with compensated cirrhosis (Child-Pugh A and selected B patients) in published trials. Liver toxicity attributable to CIK itself is uncommon. However, the underlying liver disease must be carefully assessed before treatment โ particularly viral hepatitis control, portal hypertension severity, and baseline transaminase levels. CancerFax ensures hepatology input is part of the pre-treatment assessment for all HCC patients we coordinate.
How does CancerFax help HCC patients access CIK therapy in China?
We begin by reviewing your complete HCC records โ pathology, imaging (CT/MRI), AFP trends, TACE or surgical reports, and current medications. We prepare a structured hepatobiliary oncology summary and identify the most appropriate specialist centre in China based on your disease stage, treatment history, and combination needs. We then coordinate directly with the oncology and hepatology teams at the chosen centre to confirm eligibility, obtain a treatment plan and cost estimate, and arrange consultation and logistics for your visit.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your Liver Cancer Been Treated With TACE, RFA, or Surgery?
CancerFax reviews your HCC case records and identifies whether CIK therapy as adjuvant or combination treatment is appropriate for your disease stage and prior treatment history โ then connects you with specialist hepatobiliary centres in China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.